PAK5 and hepatocellular carcinoma: Thus, we demonstrated that miRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway (Fig. 8E).